Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status

Abstract

Background Previous screening trials for early detection of ovarian cancer in postmenopausal women have used the standard CA125 cut-point of 35 U/mL, the 98th percentile in this population yielding a 2% false positive rate, while the same cut-point in trials of premenopausal women results in substantially higher false positive rates. We investigated demographic and clinical factors predicting CA125 distributions, including 98th percentiles, in a large population of high-risk women participating in two ovarian cancer screening studies with common eligibility criteria and screening protocols. Methods Baseline CA125 values and clinical and demographic data from 3,692 women participating in screening studies conducted by the NCI-sponsored Cancer Genetics Network and Gynecologic Oncology Group were combined for this pre-planned analysis. Due to the large effect of menopausal status on CA125 levels, statistical analyses were conducted separately in pre- and postmenopausal subjects to determine the impact of other baseline factors on predicted CA125 cut-points based on the 98th percentile. Results The primary clinical factor affecting CA125 cut-points was menopausal status, with premenopausal women having a significantly higher cut-point of 50 U/mL while in postmenopausal subjects the standard cut-point of 35 U/mL was recapitulated. In premenopausal women, current oral contraceptive (OC) users had a cut-point of 40 U/mL. Conclusions To achieve a 2% false positive rate in ovarian cancer screening trials and in high-risk women choosing to be screened, the cut-point for initial CA125 testing should be personalized primarily for menopausal status (~ 50 for premenopausal women, 40 for premenopausal on OC, 35 for postmenopausal women).

Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass

“…RMI translates the morphological description of the pelvic mass into objective numerical data, reducing the bias attributable to the examiner's subjectivity. This is more effective than any of the other parameters on their own, that is, ultrasound, CA125 level, menopausal status [9].…”

Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier

“…26,27 A recent study illustrated that an annual magnetic resonance imaging (MRI) decreases the risk of advanced-stage breast cancer in women with BRCA1/2 mutations. 28 Current breast cancer screening recommendations for the BRCA mutation carrier include monthly breast self-exam beginning at 18 years of age, semiannual clinical breast exam beginning at age 25, and annual mammography and breast MRI beginning at ages [25][26][27][28][29][30][31][32][33][34][35]. 25,29 Screening should be modified based on the earliest age of onset of breast cancer in a first-degree relative in a given family.…”

Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective

“…ROCA performance has been successively investigated in several multicenter trials (71)(72)(73)(74)(75). In all these investigations, the reported specificity was 99.8% and the positive predictive value was between 35.1% and 37.5%.…”